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Table 1 Patient characteristics
Characteristics No. of patients %
Age 75.0 0.7 52-94
EOD 1 73 66.4
0 37 33.6
ALP 350 47 42.7
<350 63 57.3
GS 9 54 49.1
8 56 50.9
PSA >200 42 38.2
200 68 61.8
Hb <12 81 73.6
12 29 26.4
Clinical stage D1 37 33.6
D2 73 66.4
EOD : extent of disease on bone scan ; GS : Gleason 
score ; PSA : prostate-specific antigen ; Hb : hemoglobin 
71 3278
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Table 3 HR=1
n=43 1<HR<5 n=43
HR 5 n=24
1 3 5
87.6%, 61.8%  42.7%
85.9%, 57.6%  35.8%
78.6%, 39.1%  20.4%
Table 2 Univariate and multivariate analyses
Parameter Univariate Multivariate
P value coefficient Hazard ratio 95% CI P value
Hb <12 vs Hb 12 0.013
Stage D2 vs  D1 0.031
EOD 1 vs 0 0.026
ALP 350 vs < 350 0.014
GS 9 vs 8 0.0082 0.797 2.22 0.413-0.903 0.032
PSA  >200 vs 200 0.0017 1.014 2.76 0.428-0.970 0.0084
Therapy CAB vs Monotherapy 0.63
Hb : hemoglobin ; EOD : extent of disease on bone scan ; ALP : alkaline phosphatase ; GS : Gleason score ; PSA :  
prostate-specific antigen ; CAB : combined androgen blockade
Table 3 Stratification of disease-specific survival
PSA>200 GS 9 N 110 Hazardratio
Classification of 
risk
43 1 low
+ 25 2.22 } intermediate+ 18 2.76
+ + 24 6.11 high
Fig. 3 Disease-specific survival rates according to 3 risk groups.
Using two statistically significant prognostic factors 
Gleason score and PSA , patients were stratified into 3 
risk groups : a low-risk group, consisting of patients with 
neither of two unfavorable factors ; an intermediate-risk 
group, consisting of patients with one of two unfavorable 
factors ; and a high-risk group, consisting of patients with 
two of two unfavorable factors.
Fig. 1 Prostate-specific antigen and disease-specific sur-
vival Patients with prostate-specific antigen PSA
>200 showed significantly lower survival rate than 
those with PSA 200 p=0.0017 .
Fig. 2 Gleason score and disease-specific survival Patients 
with Gleason score 9 showed significantly lower 
survival rate than those with Gleason score 8 
p=0.0082 .
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Prognostic factors in patients with advanced prostate cancer treated  
with endocrine therapy
Kenji SHIMODAIRA, Jun NAKASHIMA, Makoto OHORI, Masaaki TACHIBANA
Department of Urology, Tokyo Medical University
Abstract
In the present study, we aimed to evaluate the prognosis and prognostic factors in patients with advanced 
prostate cancer treated with endocrine therapy. This study included 110 patients with stage C or D prostate can-
cer who were treated with endocrine therapy as the primary therapy. Disease-specific survival DSS  was evalu-
ated using the Kaplan-Meier method and prognostic factors identified by Cox proportional hazard model analysis.
In the univariate analysis, we found that patients with prostate-specific antigen PSA  levels >200 ng/mL, alka-
line phosphatase 350 U/L, Gleason score 9, extent of disease on bone scan 1, hemoglobin <12 g/dL or stage 
D2 disease showed significantly lower DSS rates than their respective counterparts. In the multivariate Cox pro-
portional hazard model analysis, it was noted that Gleason score and PSA were independent prognostic factors.
Using these 2 statistically significant factors, patients were stratified into 3 risk groups. The differences in DSS 
among the 3 groups were significant. These results suggest that Gleason score and PSA are independent prog-
nostic factors and that a combination of these factors can be used to stratify DSS risk in patients with advanced 
prostate cancer treated with endocrine therapy.
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